NEW YORK (GenomeWeb) – Becton Dickinson announced this week that it has agreed to sell 50.1 percent of its respiratory solutions business to funds advised by global private equity firm Apax Partners. The new company will include all business lines within BD's respiratory solutions business including respiratory diagnostics, and will have estimated annual revenue of approximately $900 million. BD will retain 49.9 percent of the company. The transaction values the entire business today at nearly $500 million, and is expected to close in late fiscal year 2016 or early fiscal year 2017.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.